Apimeds Pharmaceuticals US, Inc
Apimeds Pharmaceuticals US, Inc
Your view on APUS
Overview
What the company does, where it operates, and who runs it.
About Apimeds Pharmaceuticals US, Inc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vinod Menon
- Headquarters
- US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vinod Menon
- Headquarters
- US
Apimeds Pharmaceuticals US, Inc. operates as a clinical stage biopharmaceutical company in the United States. It researches, develops, manufactures, commercializes, and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple sclerosis.
The company was incorporated in 2020 and is based in Hopewell, New Jersey. Apimeds Pharmaceuticals US, Inc. is a subsidiary of Api Meds, Inc.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Apimeds Pharmaceuticals US, Inc, and the rating behind it. APUS last traded at $2.10; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Apimeds Pharmaceuticals US, Inc. Starting points for Apimeds Pharmaceuticals US, Inc: EPS -$35.63, beta 0.15 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals US, Inc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Apimeds Pharmaceuticals US, Inc. Trailing twelve-month EPS for Apimeds Pharmaceuticals US, Inc stands at -$35.63. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Apimeds Pharmaceuticals US, Inc. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Apimeds Pharmaceuticals US, Inc valued side by side against its closest peers. Apimeds Pharmaceuticals US, Inc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Apimeds Pharmaceuticals US, Inc, and how their positions are changing. At a $3.2M market value, institutional positions materially move Apimeds Pharmaceuticals US, Inc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Apimeds Pharmaceuticals US, Inc executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Apimeds Pharmaceuticals US, Inc. Apimeds Pharmaceuticals US, Inc is a $3.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Apimeds Pharmaceuticals US, Inc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Apimeds Pharmaceuticals US, Inc. Coverage tracks Apimeds Pharmaceuticals US, Inc within Biotechnology (Healthcare). Press releases and market coverage, newest first.